Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
31 mai 2023 07h00 HE
|
Selecta Biosciences, Inc.
- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo...
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
04 mai 2023 07h30 HE
|
Selecta Biosciences, Inc.
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31,...
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
28 avr. 2023 16h05 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
19 nov. 2020 08h00 HE
|
Selecta Biosciences, Inc.
RESEARCH TRIANGLE PARK, N.C. and WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the...
Selecta Biosciences to Participate in Upcoming Investor Conferences
10 nov. 2020 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
05 nov. 2020 07h30 HE
|
Selecta Biosciences, Inc.
Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights
29 oct. 2020 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
20 oct. 2020 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S....
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
08 oct. 2020 16h05 HE
|
Selecta Biosciences, Inc.
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN) Selecta’s IgA nephropathy program builds upon...
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout
30 sept. 2020 16h15 HE
|
Selecta Biosciences, Inc.
All data consistent with stronger performance of SEL-212 versus pegloticase Numerically higher response rate for SEL-212 versus pegloticase during primary endpoint of months 3 and 6 combined;...